TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS AND OTHER PROGRESSING INTERSTITIAL FIBROSING LUNG DISEASES USING NINTEDANIB

Abstract

Nintedanib is an intracellular tyrosine kinase receptor inhibitor, an antifibrotic drug approved for the treatment of idiopathic pulmonary fibrosis (IPF). New guidelines for IPF and progressive pulmonary fibrosis (PPF) for adults were released in 2022. According to these recommendations and clinical trials, nintedanib efficacy was approved for interstitial lung diseases with PPF.